Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus

摘要: Diabetic patients are at increased risk of complicated skin, skin structure and bone infections including diabetic foot ulcerations (DFU). Analyses epidemiology microbial pathogenicity show that staphylococci seem to be predestined induce such infections. In addition, multidrug resistance particularly due an increasing prevalence methicillin-resistant Staphylococcus aureus (MRSA) seems the challenge for effective antibiotic therapy. With regard with MRSA, classical agents like vancomycin, linezolid, fosfomycin or trimethroprim-sulphametoxazol might choice in DFU. New-generation drugs broad-spectrum tetracyclines tigecycline, first second generation cyclic lipopeptides, anti-MRSA β-lactams ceftobiprole antibodies developed progress hope future.